Basilea Pharmaceutica Ltd (BPMUF)
48.15
0.00 (0.00%)
USD |
OTCM |
May 24, 16:00
Basilea Pharmaceutica Total Liabilities (Quarterly): 218.22M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 218.22M |
| June 30, 2023 | 239.14M |
| June 30, 2023 | 239.14M |
| December 31, 2022 | 260.54M |
| June 30, 2022 | 317.74M |
| June 30, 2022 | 317.74M |
| December 31, 2021 | 334.62M |
| June 30, 2021 | 332.17M |
| June 30, 2021 | 332.17M |
| December 31, 2020 | 379.82M |
| June 30, 2020 | 290.85M |
| June 30, 2020 | 290.85M |
| December 31, 2019 | 324.51M |
| June 30, 2019 | 323.11M |
| June 30, 2019 | 323.11M |
| December 31, 2018 | 353.91M |
| June 30, 2018 | 364.17M |
| June 30, 2018 | 364.17M |
| December 31, 2017 | 403.05M |
| June 30, 2017 | 360.57M |
| June 30, 2017 | 360.57M |
| Date | Value |
|---|---|
| December 31, 2016 | 356.50M |
| June 30, 2016 | 361.96M |
| June 30, 2016 | 361.96M |
| December 31, 2015 | 388.37M |
| June 30, 2015 | 221.13M |
| June 30, 2015 | 221.13M |
| December 31, 2014 | 201.70M |
| June 30, 2014 | 226.89M |
| June 30, 2014 | 226.89M |
| December 31, 2013 | 257.90M |
| June 30, 2013 | 261.52M |
| June 30, 2013 | 261.52M |
| December 31, 2012 | 295.59M |
| June 30, 2012 | 71.61M |
| June 30, 2012 | 71.61M |
| December 31, 2011 | 89.12M |
| June 30, 2011 | 103.29M |
| December 31, 2010 | 113.72M |
| June 30, 2010 | 139.75M |
| December 31, 2009 | 105.14M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
218.22M
Minimum
Dec 2023
379.82M
Maximum
Dec 2020
301.58M
Average
317.74M
Median
Jun 2022
Total Liabilities (Quarterly) Benchmarks
| AC Immune SA | 25.05M |
| CRISPR Therapeutics AG | 355.08M |
| Addex Therapeutics Ltd | 4.163M |
| NLS Pharmaceutics Ltd | 10.68M |
| Molecular Partners AG | 18.91M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 206.31M |
| Shareholders Equity (Quarterly) | -11.91M |
| Debt to Equity Ratio | -11.09 |
| Current Ratio | 3.197 |
| Net Debt Paydown Yield | 6.10% |